Replies to post #243006 on Biotech Values

[swampboots]

Cart-T gene editing should improve as this field expands ability to spot where genes are in the targeted tissues:

"Computational and experimental methods are bringing researchers closer to their goal of revealing exactly where in a cell or tissue each gene is expressed."

https://www.nature.com/articles/d41586-022-01743-7?utm_source=Nature+Briefing&utm_campaign=b4de217ba9-briefing-dy-20220628&utm_medium=email&utm_term=0_c9dfd39373-b4de217ba9-44970129

[swampboots]

DTIL 1.53.

Truth be told, I know nothing about the prospects of this stock to yield a net profit.
Insider selling and their funding principle to attract partners, capturing Lilly and Novartis and others already ,with more insider buying from their top execs. tilts to me, a higher probable promise than suppositions I could surmise absent those facts.

The video (I linked) however suggests to me, that DTIL is the most promising scalable medical stock I can think of, even if true its ultimate success will lead to complete unfortunate failure.
The idea that this gene editing platform can conceivably be used to be effective for at least 7K diseases is crucial to proclaim its surpassing promise. The rapid new developments in new computational and experimental methods can avail foreseeing continuous increased effectiveness of this platform, even after periods of enduring inconclusive failure.

Bottom line: I can not recommend as a wise investment the stock DTIL,
But when I match DTIL against all possible investments in charitable enterprises, with the expectations of deriving no profit except tax benefits , I think DTIL is also eligible to receive a "philanthropic" donation, with no prospects of a return, except, to just be able to say, when asked to donate money for some disease, the words "I already gave".

Anyway,if anyone can name a stock with more promising scalable prospects than DTIL, it would to the highest degree, tease my curiosity.